APO Research
Talk to an analyst

APO RESEARCH · REPORT

Syndromic Diagnostic Test

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Syndromic Diagnostic Test Market Outlook and Growth Opportunities 2026

2 May 2026194 pages

Choose your research edition.

Industry ResearchSyndromic Diagnostic Test Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Syndromic Diagnostic Test Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Syndromic Diagnostic Test Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Syndromic Diagnostic Test Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Syndromic Diagnostic Test Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Syndromic Diagnostic Test market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Syndromic Diagnostic Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Syndromic Diagnostic Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Syndromic Diagnostic Test is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Syndromic Diagnostic Test market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Syndromic Diagnostic Test market include Abbott, Hologic, Applied BioCode, Danaher, Diagenode, Curetis, Bio-Rad, DiaSorin and bioMérieux, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Syndromic Diagnostic Test market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Syndromic Diagnostic Test and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Syndromic Diagnostic Test revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Syndromic Diagnostic Test market.

Syndromic Diagnostic Test Segment by Company

Abbott

Hologic

Applied BioCode

Danaher

Diagenode

Curetis

Bio-Rad

DiaSorin

bioMérieux

QIAGEN

Syndromic Diagnostic Test Segment by Type

Nucleic Acid Extraction Test

Polymerase Chain Reaction (PCR) Test

Others

Syndromic Diagnostic Test Segment by Application

Hospital

Laboratory

Research Institution

Others

Syndromic Diagnostic Test Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Syndromic Diagnostic Test status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Syndromic Diagnostic Test key companies, revenue, market share, and recent developments.

3. To split the Syndromic Diagnostic Test breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Syndromic Diagnostic Test market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Syndromic Diagnostic Test significant trends, drivers, influence factors in global and regions.

6. To analyze Syndromic Diagnostic Test competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Syndromic Diagnostic Test market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Syndromic Diagnostic Test and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Syndromic Diagnostic Test.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Syndromic Diagnostic Test industry.

Chapter 3: Detailed analysis of Syndromic Diagnostic Test company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Syndromic Diagnostic Test in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Syndromic Diagnostic Test in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Syndromic Diagnostic Test Industry Trends Table 2. Syndromic Diagnostic Test Industry Drivers Table 3. Syndromic Diagnostic Test Industry Opportunities and Challenges Table 4. Syndromic Diagnostic Test Industry Restraints Table 5. Global Syndromic Diagnostic Test Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Syndromic Diagnostic Test Revenue Share by Company (2021-2026) Table 7. Global Syndromic Diagnostic Test Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Syndromic Diagnostic Test Key Company Manufacturing Base & Headquarters Table 9. Global Syndromic Diagnostic Test Company, Product Type & Application Table 10. Global Syndromic Diagnostic Test Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Syndromic Diagnostic Test by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Nucleic Acid Extraction Test Table 15. Significant Companies of Polymerase Chain Reaction (PCR) Test Table 16. Significant Companies of Others Table 17. Global Syndromic Diagnostic Test Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Syndromic Diagnostic Test Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Syndromic Diagnostic Test Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Syndromic Diagnostic Test Sales Value Share by Type (2021-2026) Table 21. Global Syndromic Diagnostic Test Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Laboratory Table 24. Significant Companies of Research Institution Table 25. Significant Companies of Others Table 26. Global Syndromic Diagnostic Test Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Syndromic Diagnostic Test Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Syndromic Diagnostic Test Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Syndromic Diagnostic Test Sales Value Share by Application (2021-2026) Table 30. Global Syndromic Diagnostic Test Sales Value Share by Application (2027-2032) Table 31. Global Syndromic Diagnostic Test Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Syndromic Diagnostic Test Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Syndromic Diagnostic Test Sales Value Share by Region (2021-2026) Table 34. Global Syndromic Diagnostic Test Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Syndromic Diagnostic Test Sales Value Share by Region (2027-2032) Table 36. Global Syndromic Diagnostic Test Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Syndromic Diagnostic Test Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Syndromic Diagnostic Test Sales Value Market Share by Country (2021-2026) Table 39. Global Syndromic Diagnostic Test Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Syndromic Diagnostic Test Sales Value Market Share by Country (2027-2032) Table 41. Abbott Company Information Table 42. Abbott Business Overview Table 43. Abbott Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Abbott Syndromic Diagnostic Test Product Portfolio Table 45. Abbott Recent Development Table 46. Hologic Company Information Table 47. Hologic Business Overview Table 48. Hologic Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Hologic Syndromic Diagnostic Test Product Portfolio Table 50. Hologic Recent Development Table 51. Applied BioCode Company Information Table 52. Applied BioCode Business Overview Table 53. Applied BioCode Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Applied BioCode Syndromic Diagnostic Test Product Portfolio Table 55. Applied BioCode Recent Development Table 56. Danaher Company Information Table 57. Danaher Business Overview Table 58. Danaher Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Danaher Syndromic Diagnostic Test Product Portfolio Table 60. Danaher Recent Development Table 61. Diagenode Company Information Table 62. Diagenode Business Overview Table 63. Diagenode Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Diagenode Syndromic Diagnostic Test Product Portfolio Table 65. Diagenode Recent Development Table 66. Curetis Company Information Table 67. Curetis Business Overview Table 68. Curetis Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Curetis Syndromic Diagnostic Test Product Portfolio Table 70. Curetis Recent Development Table 71. Bio-Rad Company Information Table 72. Bio-Rad Business Overview Table 73. Bio-Rad Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bio-Rad Syndromic Diagnostic Test Product Portfolio Table 75. Bio-Rad Recent Development Table 76. DiaSorin Company Information Table 77. DiaSorin Business Overview Table 78. DiaSorin Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. DiaSorin Syndromic Diagnostic Test Product Portfolio Table 80. DiaSorin Recent Development Table 81. bioMérieux Company Information Table 82. bioMérieux Business Overview Table 83. bioMérieux Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. bioMérieux Syndromic Diagnostic Test Product Portfolio Table 85. bioMérieux Recent Development Table 86. QIAGEN Company Information Table 87. QIAGEN Business Overview Table 88. QIAGEN Syndromic Diagnostic Test Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. QIAGEN Syndromic Diagnostic Test Product Portfolio Table 90. QIAGEN Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Syndromic Diagnostic Test Product Image Figure 2. Global Syndromic Diagnostic Test Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Syndromic Diagnostic Test Market Size (2021-2032) & (US$ Million) Figure 4. Global Syndromic Diagnostic Test Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Nucleic Acid Extraction Test Image Figure 8. Polymerase Chain Reaction (PCR) Test Image Figure 9. Others Image Figure 10. Global Syndromic Diagnostic Test Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Syndromic Diagnostic Test Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Syndromic Diagnostic Test Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Laboratory Image Figure 15. Research Institution Image Figure 16. Others Image Figure 17. Global Syndromic Diagnostic Test Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Syndromic Diagnostic Test Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Syndromic Diagnostic Test Sales Value Share by Application (2021-2032) Figure 20. Global Syndromic Diagnostic Test Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Syndromic Diagnostic Test Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Syndromic Diagnostic Test Sales Value (2021-2032) & (US$ Million) Figure 23. North America Syndromic Diagnostic Test Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Syndromic Diagnostic Test Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Syndromic Diagnostic Test Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Syndromic Diagnostic Test Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Syndromic Diagnostic Test Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Syndromic Diagnostic Test Sales Value (2021-2032) & (US$ Million) Figure 29. South America Syndromic Diagnostic Test Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Syndromic Diagnostic Test Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Syndromic Diagnostic Test Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Nucleic Acid Extraction Test
  • Polymerase Chain Reaction (PCR) Test
  • Others
Applications
  • Hospital
  • Laboratory
  • Research Institution
  • Others
Companies covered
  • Abbott
  • Hologic
  • Applied BioCode
  • Danaher
  • Diagenode
  • Curetis
  • Bio-Rad
  • DiaSorin
  • bioMérieux
  • QIAGEN

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Syndromic Diagnostic Test Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Syndromic Diagnostic Test Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Syndromic Diagnostic Test Market Dynamics
  1. 2.1 Syndromic Diagnostic Test Industry Trends
  2. 2.2 Syndromic Diagnostic Test Industry Drivers
  3. 2.3 Syndromic Diagnostic Test Industry Opportunities and Challenges
  4. 2.4 Syndromic Diagnostic Test Industry Restraints
3 Syndromic Diagnostic Test Market by Company
  1. 3.1 Global Syndromic Diagnostic Test Company Revenue Ranking in 2025
  2. 3.2 Global Syndromic Diagnostic Test Revenue by Company (2021-2026)
  3. 3.3 Global Syndromic Diagnostic Test Company Ranking (2024-2026)
  4. 3.4 Global Syndromic Diagnostic Test Company Manufacturing Base and Headquarters
  5. 3.5 Global Syndromic Diagnostic Test Company Product Type and Application
  6. 3.6 Global Syndromic Diagnostic Test Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Syndromic Diagnostic Test Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Syndromic Diagnostic Test Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Syndromic Diagnostic Test Market by Type
  1. 4.1 Syndromic Diagnostic Test Type Introduction
  2. 4.1.1 Nucleic Acid Extraction Test
  3. 4.1.2 Polymerase Chain Reaction (PCR) Test
  4. 4.1.3 Others
  5. 4.2 Global Syndromic Diagnostic Test Sales Value by Type
  6. 4.2.1 Global Syndromic Diagnostic Test Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Syndromic Diagnostic Test Sales Value by Type (2021-2032)
  8. 4.2.3 Global Syndromic Diagnostic Test Sales Value Share by Type (2021-2032)
5 Syndromic Diagnostic Test Market by Application
  1. 5.1 Syndromic Diagnostic Test Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Laboratory
  4. 5.1.3 Research Institution
  5. 5.1.4 Others
  6. 5.2 Global Syndromic Diagnostic Test Sales Value by Application
  7. 5.2.1 Global Syndromic Diagnostic Test Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Syndromic Diagnostic Test Sales Value by Application (2021-2032)
  9. 5.2.3 Global Syndromic Diagnostic Test Sales Value Share by Application (2021-2032)
6 Syndromic Diagnostic Test Regional Value Analysis
  1. 6.1 Global Syndromic Diagnostic Test Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Syndromic Diagnostic Test Sales Value by Region (2021-2032)
  3. 6.2.1 Global Syndromic Diagnostic Test Sales Value by Region: 2021-2026
  4. 6.2.2 Global Syndromic Diagnostic Test Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Syndromic Diagnostic Test Sales Value (2021-2032)
  7. 6.3.2 North America Syndromic Diagnostic Test Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Syndromic Diagnostic Test Sales Value (2021-2032)
  10. 6.4.2 Europe Syndromic Diagnostic Test Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Syndromic Diagnostic Test Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Syndromic Diagnostic Test Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Syndromic Diagnostic Test Sales Value (2021-2032)
  16. 6.6.2 South America Syndromic Diagnostic Test Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Syndromic Diagnostic Test Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Syndromic Diagnostic Test Sales Value Share by Country, 2025 VS 2032
7 Syndromic Diagnostic Test Country-level Value Analysis
  1. 7.1 Global Syndromic Diagnostic Test Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Syndromic Diagnostic Test Sales Value by Country (2021-2032)
  3. 7.2.1 Global Syndromic Diagnostic Test Sales Value by Country (2021-2026)
  4. 7.2.2 Global Syndromic Diagnostic Test Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Syndromic Diagnostic Test Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Syndromic Diagnostic Test Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Syndromic Diagnostic Test Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Syndromic Diagnostic Test Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Hologic
  8. 8.2.1 Hologic Company Information
  9. 8.2.2 Hologic Business Overview
  10. 8.2.3 Hologic Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Hologic Syndromic Diagnostic Test Product Portfolio
  12. 8.2.5 Hologic Recent Developments
  13. 8.3 Applied BioCode
  14. 8.3.1 Applied BioCode Company Information
  15. 8.3.2 Applied BioCode Business Overview
  16. 8.3.3 Applied BioCode Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Applied BioCode Syndromic Diagnostic Test Product Portfolio
  18. 8.3.5 Applied BioCode Recent Developments
  19. 8.4 Danaher
  20. 8.4.1 Danaher Company Information
  21. 8.4.2 Danaher Business Overview
  22. 8.4.3 Danaher Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Danaher Syndromic Diagnostic Test Product Portfolio
  24. 8.4.5 Danaher Recent Developments
  25. 8.5 Diagenode
  26. 8.5.1 Diagenode Company Information
  27. 8.5.2 Diagenode Business Overview
  28. 8.5.3 Diagenode Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Diagenode Syndromic Diagnostic Test Product Portfolio
  30. 8.5.5 Diagenode Recent Developments
  31. 8.6 Curetis
  32. 8.6.1 Curetis Company Information
  33. 8.6.2 Curetis Business Overview
  34. 8.6.3 Curetis Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Curetis Syndromic Diagnostic Test Product Portfolio
  36. 8.6.5 Curetis Recent Developments
  37. 8.7 Bio-Rad
  38. 8.7.1 Bio-Rad Company Information
  39. 8.7.2 Bio-Rad Business Overview
  40. 8.7.3 Bio-Rad Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Rad Syndromic Diagnostic Test Product Portfolio
  42. 8.7.5 Bio-Rad Recent Developments
  43. 8.8 DiaSorin
  44. 8.8.1 DiaSorin Company Information
  45. 8.8.2 DiaSorin Business Overview
  46. 8.8.3 DiaSorin Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  47. 8.8.4 DiaSorin Syndromic Diagnostic Test Product Portfolio
  48. 8.8.5 DiaSorin Recent Developments
  49. 8.9 bioMérieux
  50. 8.9.1 bioMérieux Company Information
  51. 8.9.2 bioMérieux Business Overview
  52. 8.9.3 bioMérieux Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  53. 8.9.4 bioMérieux Syndromic Diagnostic Test Product Portfolio
  54. 8.9.5 bioMérieux Recent Developments
  55. 8.10 QIAGEN
  56. 8.10.1 QIAGEN Company Information
  57. 8.10.2 QIAGEN Business Overview
  58. 8.10.3 QIAGEN Syndromic Diagnostic Test Revenue and Gross Margin (2021-2026)
  59. 8.10.4 QIAGEN Syndromic Diagnostic Test Product Portfolio
  60. 8.10.5 QIAGEN Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst